Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 5.9% - Should You Buy?

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) shot up 5.9% on Monday . The company traded as high as $22.72 and last traded at $23.05. 80,071 shares changed hands during mid-day trading, a decline of 91% from the average session volume of 898,683 shares. The stock had previously closed at $21.76.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on GPCR. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price objective on shares of Structure Therapeutics in a report on Tuesday. William Blair assumed coverage on Structure Therapeutics in a report on Friday, February 28th. They issued an "outperform" rating for the company. Finally, Stifel Nicolaus started coverage on shares of Structure Therapeutics in a research report on Wednesday, January 8th. They issued a "buy" rating and a $50.00 price objective on the stock. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $81.29.

Structure Therapeutics Stock Up 0.4 %

The stock has a market capitalization of $1.36 billion, a P/E ratio of -32.08 and a beta of -1.35. The stock's 50 day moving average price is $20.17 and its 200-day moving average price is $27.87.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. Analysts anticipate that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Hedge Funds Weigh In On Structure Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Handelsbanken Fonder AB boosted its stake in Structure Therapeutics by 130.3% during the first quarter. Handelsbanken Fonder AB now owns 380,000 shares of the company's stock worth $6,578,000 after buying an additional 215,000 shares during the last quarter. GAMMA Investing LLC increased its holdings in Structure Therapeutics by 663.8% in the 1st quarter. GAMMA Investing LLC now owns 8,776 shares of the company's stock valued at $152,000 after purchasing an additional 7,627 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Structure Therapeutics in the 4th quarter valued at $3,091,000. GF Fund Management CO. LTD. acquired a new stake in shares of Structure Therapeutics during the fourth quarter worth about $34,000. Finally, Woodline Partners LP boosted its position in Structure Therapeutics by 0.7% in the 4th quarter. Woodline Partners LP now owns 333,901 shares of the company's stock valued at $9,055,000 after buying an additional 2,328 shares during the period. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.